title: OARSI/OMERACT criteria of being considered a candidate for total joint replacement in knee/hip osteoarthritis as an endpoint in clinical trials evaluating potential disease modifying osteoarthritic drugs.
abstract: OBJECTIVE
  A disease-modifying osteoarthritic drug (DMOAD) should interfere with the cartilage breakdown observed and improve symptoms or prevent deterioration of the patient's clinical condition. We propose a composite index including structural and symptomatic variables of osteoarthritis (OA) as criteria for being considered a candidate for total joint replacement as an endpoint in clinical trials evaluating potential DMOAD.
  
  
  METHODS
  An OARSI/OMERACT task force conducted this study in 3 steps: (1) The 3 main domains -- pain, function, structure -- were revisited; (2) For each of the domains a "non-acceptable state" and a "relevant" progression for their structure were defined; and (3) a set of criteria was proposed combining the information from these 3 domains.
  
  
  RESULTS
  A questionnaire was elaborated for the domains "pain" and "function." Systematic research of the literature and evaluation of different databases concluded that the domain "structure" should be evaluated by radiological joint space width in millimeters. An unacceptable radiographic progression was defined as a change in the joint space width over the measurement error. An international, cross-sectional study is proposing a definition of a "nonacceptable symptom state."
  
  
  CONCLUSIONS
  The objective of the ongoing OARSI/OMERACT initiative is to propose criteria for being considered a candidate for total joint replacement to be used as an endpoint in clinical trials evaluating potential DMOAD. The preliminary steps of this initiative have been completed.
authors.affiliation: Paris-Descartes University, Medicine Faculty, UPRES EA 4058, AP-HP, Cochin Hospital, Rheumatology B Department, Paris, France. maxime.dougados@cch.aphp.fr
authors.forename: Maxime
authors.initials: M
authors.lastname: Dougados
authors.forename: Gillian
authors.initials: G
authors.lastname: Hawker
authors.forename: Stefan
authors.initials: S
authors.lastname: Lohmander
authors.forename: Aileen M
authors.initials: AM
authors.lastname: Davis
authors.forename: Paul
authors.initials: P
authors.lastname: Dieppe
authors.forename: Jean-Francis
authors.initials: JF
authors.lastname: Maillefert
authors.forename: Laure
authors.initials: L
authors.lastname: Gossec
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D018771:Arthralgia / Q000503:physiopathology; D019644:Arthroplasty, Replacement, Hip; D019645:Arthroplasty, Replacement, Knee; D018450:Disease Progression; D023381:Endpoint Determination; D006306:Health Surveys; D006801:Humans; D015207:Osteoarthritis, Hip / Q000188:drug therapy / Q000503:physiopathology / Q000601:surgery*; D020370:Osteoarthritis, Knee / Q000188:drug therapy / Q000503:physiopathology / Q000601:surgery*; D018579:Patient Selection; D012720:Severity of Illness Index
chemical_list: D018501:Antirheumatic Agents